Global Research Antibodies Market Worth USD 8.75 Billion By 2031 | CAGR of 6.03%

Introduction

Antibodies are immune system proteins produced in response to the appearance of a pathogen (known as an antigen). Research antibodies detect an unconjugated primary antibody, which is then used to target antigen. Research laboratory procedures, such as western blotting and others, rely on research antibodies, which are indispensable tools for these procedures. Antibodies used in scientific research are crucial detection methods. Antibodies can also be used to designate and identify specific proteins present in a diseased cell at a specific stage of the disease's life cycle to determine why a cell function has gone awry.

Market Dynamics

Increasing Investment in R&D Drives the Global Market

Numerous prominent biopharmaceutical, pharmaceutical, and biotechnology firms have increased their R&D efforts to develop innovative antibodies, including monoclonal antibodies. In 2016, Novartis invested USD 9 billion in research and development, whereas Pfizer invested USD 7.9 billion to develop novel products and technologies in the same year. In addition, research antibodies are complex and sophisticated structures increasingly utilized in research and academic institutions and by major pharmaceutical and biotechnology companies, thereby garnering R&D investments to develop advanced generations of antibodies. The frequency of cancer and other chronic diseases has increased the demand for research and development in research antibodies, driving market growth.

Growing Products Launches by Industry Participants Creates Tremendous Opportunities

Participants in the market are working on product approvals, which are expected to accelerate the growth of the global market for research antibodies over the forecast period. For instance, the U.S. FDA approved Tepezza (TM) (teprotumumab-trbw), a therapeutic monoclonal antibody for treating thyroid eye disease, on January 21, 2020. In addition, Horizon Therapeutics plc is a biopharmaceutical corporation devoted to pharmaceutical research, development, and marketing (TED). TED is an uncommon, severe, and vision-threatening autoimmune disease that causes proptosis (eye bulging), diplopia (double vision), impaired vision, discomfort, inflammation, and facial deformities. Tepezza is the only treatment for TED that has been approved by the FDA (Food and Drug Administration) of the United States. These factors are anticipated to provide market expansion opportunities.

Regional Analysis

North America is the most significant global research antibodies market shareholder and is anticipated to exhibit a CAGR of 4.8% during the forecast period. The United States and Canada are North America's most important nations. Antibody industry growth in North America is anticipated to be fueled by novel product introductions. The presence of numerous biotechnology and biopharmaceutical manufacturers, research institutes, and substantial economic growth are significant factors driving the North American market for research antibodies. In addition, the manufacturers of research antibodies concentrate on developing, marketing, and distributing innovative products to meet the requirements of researchers and healthcare professionals. High healthcare costs in North America propel the market for research antibodies.

Europe is estimated to exhibit a CAGR of 5.2% over the forecast period. The substantial proportion attained by the region is a result of the increase in research activities over the past few years. Consistent growth has encouraged researchers to utilize advanced reagents and antibodies to accelerate research, contributing to market expansion. Affinomics, a program launched by the European Union (EU) to promote the adoption of recombinant technologies, is amongst the main factors responsible for expanding growth prospects over the past few years. This region's development is accelerated by the increasing number of initiatives by clinicians and scientists to raise awareness of the availability of various types of antibodies suited to specific research needs. In addition, antibody production guidelines issued by public organizations assure the quality of research antibodies, resulting in a greater reliance on researchers and clinicians, contributing to the demand for research antibodies in the coming years.

Key Highlights

• The global research antibodies market size was valued at USD 6.2 billion in 2022. It is estimated to reach USD 8.75 billion by 2031, growing at a CAGR of 6.03% during the forecast period (2023–2031).
• Based on the product, the global research antibodies market is bifurcated into primary and secondary antibodies. The primary antibodies segment is the most significant contributor to the market share and is anticipated to exhibit a CAGR of 6.31% over the forecast period.
• Based on type, the global research antibodies market is divided into monoclonal and polyclonal antibodies. The monoclonal antibody segment dominates the global market and is projected to exhibit a CAGR of 6.5% over the forecast period.
• Based on technology, the global research antibodies market is bifurcated into immunohistochemistry, western blotting, immunofluorescence, flow cytometry, ELISA, immunoprecipitation, and others. The western blotting segment is the most significant contributor to the market share and is anticipated to exhibit a CAGR of 5.71% over the forecast period.
• Based on the source, the global research antibodies market is segmented into mouse, rabbit, goat, and others. The mouse segment is the largest revenue contributor to the market and is projected to exhibit a CAGR of 6.1% over the forecast period.
• Based on application, the global research antibodies market is divided into infectious diseases, oncology, immunology, neurobiology, stem cells, and others. The oncology segment dominates the global market and is expected to grow at a CAGR of 5.71% over the forecast period.
• Based on end-user, the global research antibodies market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations. The pharmaceutical and biotechnology companies segment owns the highest market share and is projected to exhibit a CAGR of 6.5% during the forecast period.
• North America is the most significant global research antibodies market shareholder and is anticipated to exhibit a CAGR of 4.8% during the forecast period.

Competitive Players

Competitive Players

The key global research antibodies market players are Abcam Plc, Merck Millipore, Thermo Fisher Scientific, Inc., Cell Signalling Technology, Inc., PerkinElmer, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Lonza Group, Agilent Technologies, and F. Hoffmann La Roche Ltd.

Recent Developments

Market News

• In April 2023, Astellas Pharma and Twist Bioscience partnered to assist the former with discovering antibodies for immunotherapies.
• In April 2023, Innate Pharma SA revealed that it had signed an exclusive license contract with Takeda. Under the terms of the agreement, Innate allows Takeda exclusive global rights to research and develop antibody-drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus on Celiac disease.

Segmentation

Global Research Antibodies Market: Segmentation

By Product

• Primary Antibodies
• Secondary Antibodies

By Type

• Monoclonal Antibodies
• Polyclonal Antibodies

By Technology

• Immunohistochemistry
• Immunofluorescence
• Western Blotting
• Flow Cytometry
• Immunoprecipitation
• Enzyme-linked Immunoassay
• Others

By Source

• Mouse
• Rabbit
• Goat
• Others

By Applications

• Infectious Diseases
• Immunology
• Oncology
• Stem Cells
• Neurobiology
• Others

By End-User

• Academic and Research Institutes
• Contract Research Organizations
• Pharmaceutical and Biotechnological Companies

By Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa